Nanyang Ventures
3
3M
3
2
3
- Areas of investment
Summary
The fund was located in Australia. The main department of described VC is located in the Sydney.
The fund is generally included in less than 2 deals every year. The real fund results show that this VC is 47 percentage points more often commits exit comparing to other companies. The important activity for fund was in 2005. The usual things for fund are deals in the range of 1 - 5 millions dollars. Opposing the other organizations, this Nanyang Ventures works on 71 percentage points more the average amount of lead investments. The higher amount of exits for fund were in 2008.
The overall number of key employees were 1.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - Australia. Among the most popular fund investment industries, there are Health Care, Information Technology. Among the most popular portfolio startups of the fund, we may highlight Catapult Genetics, TGR BioSciences, QRxPharma. Besides, a startup needs to be aged 4-5 years to get the investment from the fund.
The standard case for the fund is to invest in rounds with 2 partakers. Despite the Nanyang Ventures, startups are often financed by Kestrel Capital. The meaningful sponsors for the fund in investment in the same round are Uniseed Ventures, Spring Ridge Ventures, Innovation Capital. In the next rounds fund is usually obtained by Plymouth Growth Partners.
Investments analytics
Analytics
- Total investments
- 3
- Lead investments
- 2
- Exits
- 3
- Investments by industry
- Biotechnology (3)
- Biopharma (1)
- Health Care (1)
- Information Technology (1)
- Genetics (1)
- Investments by region
-
- Australia (3)
- Peak activity year
- 2005
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 21
- Group Appearance index
- 0.33
- Avg. company exit year
- 14
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| QRxPharma | 10 Dec 2002 | Biotechnology, Health Care, Biopharma | Early Stage Venture | 5M | New South Wales, Sydney, Australia |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.